Janet M. D. Plate

Janet M. D. Plate

Auto-generated profile, based on publicly available information

Janet M. D. Plate

Division of Hematology, Oncology and Cell Therapy, Section of Medical Oncology, Rush University Medical Center, Chicago, IL 60612, USA

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2005 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
JPJanet M. D. Plate
Janet M. D. Plate
APAileen E. Plate
Aileen E. Plate
SSSusan Shott
Susan Shott
SBSusan Bograd
Susan Bograd
JHJules E. Harris
Jules E. Harris

23 May 2011 in BMC Cancer
Verified
Journal Article
Open access
PDF file
XXXiulong Xu
Xiulong Xu
GRGeetha S Rao
Geetha S Rao
VGVeronika Groh
Veronika Groh
TSThomas Spies
Thomas Spies
PGPaolo Gattuso
Paolo Gattuso
RPRichard Prinz
Richard Prinz
Major histocompatibility complex class I-related chain A and B (MICA/B) are two stress-inducible ligands that bind the immunoreceptor NKG2D and play an important role in mediating the cyotoxicity of NK and T cells. In this study, we sought to study MICA/B expression in pancreatic cancer and to determine whether and how genotoxic drugs such as gemcitabine can affect MICA/B expression and natural killer cytotoxity.

26 August 2004 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
JPJanet Md Plate
Janet Md Plate
(2004). PI3-Kinase Regulates Survival of Chronic Lymphocytic Leukemia B-Cells by Preventing Caspase 8 Activation. Leukemia & Lymphoma: Vol. 45, No. 8, pp. 1519-1529.

1 January 2000 in Critical Reviews in Immunology
Verified
Journal Article
Closed access
JPJanet M. D. Plate
Janet M. D. Plate
JHJules E. Harris
Jules E. Harris
Pancreatic cancer kills nearly 29,000 people in the United States annually—as many people as are diagnosed with the disease. Chemotherapeutic treatment is ineffective in halting progression of the disease. Yet, specific immunity to pancreatic tumor cells in subjects with pancreatic cancer has been demonstrated repeatedly during the last 24 years. Attempts to expand and enhance tumor-specific immunity with biotherapy, however, have not met with success. The question remains, "Why can't specific immunity regulate pancreatic cancer growth?" The idea that tumor cells have evolved protective mechanisms against immunity was raised years ago and has recently been revisited by a number of research laboratories. In pancreatic cancer, soluble factors produced by and for the protection of the tumor environment have been detected and are often distributed to the victim's circulatory system where they may effect a more generalized immunosuppression. Yet the nature of these soluble factors remains controversial, since some also serve as tumor antigens that are recognized by the same T cells that may become inactivated by them. Unless the problem of tumor-derived immunosuppressive products is addressed directly through basic and translational research studies, successful biotherapeutic treatment for pancreatic cancer may not be forthcoming.

1 June 2011 in Expert Review of Vaccines
Verified
Journal Article
Closed access
JPJanet Plate
Janet Plate
A greater understanding of the molecular events that trigger oncogenesis and events that negatively regulate immune responses has allowed for the development of targeted therapies with specific vaccines to match tumor antigens coupled with immunotherapy specifically directed against that tumor's immunosuppressive microenvironment. In order to be effective, vaccine therapies need to both expand the immune response to tumors and overcome immunosuppressive microenvironments therein. Specifically, targeted therapy must be personalized for each cancer patient. While the idea of personalized targeted therapy may seem like a daunting task, it may not be that difficult as it could involve a relatively simple genetic test to identify gene mutations and additional immunohistochemical staining of tumors with antibodies directed against markers of negative immune regulation. The additional cost to personalize cancer therapy with these diagnostic tests is relatively small in comparison to the cost afforded to our healthcare system when inappropriate targeting therapies are administered to patients whose tumors do not express the targets of either the vaccine or the immune modulator. Despite the large cost, cancer patients whose tumors lack the targets of these therapies often receive no benefit from the therapy. The most illogical approach is to develop a study design and perform clinical trials of potential novel targeting drugs without knowledge or confirmation that the patients' tumors express the targets. Current cancer trials for pancreatic cancer patients are discussed in this article.

1 November 2000 in Experimental Hematology
Verified
Journal Article
Closed access
JPJanet M.D Plate
Janet M.D Plate
KPKathryn S Petersen
Kathryn S Petersen
LBLela Buckingham
Lela Buckingham
HSHomayoun Shahidi
Homayoun Shahidi
CSClaude M Schofield
Claude M Schofield